41764-74-3

Basic information

• Product Name: 3,4-DIMETHOXYBENZHYDRAZIDE
• Synonyms: 3,4-DIMETHOXYBENZOYL HYDRAZINE;3,4-DIMETHOXY BENZOIC ACID HYDRAZIDE;3,4-DIMETHOXYBENZHYDRAZIDE;3,4-DIMETHOXYBENZENECARBOHYDRAZIDE;AKOS BBS-00000720;AKOS BBB/170;AKOS BC-1521;VERATRIC ACID HYDRAZIDE
• CAS NO: 41764-74-3
• Molecular Formula: C₉H₁₂N₂O₃
• Molecular Weight: 196.2
• EINECS: 255-541-7
• Product Categories: Aromatic Hydrazides, Hydrazines, Hydrazones and Oximes
• Mol File: 41764-74-3.mol
• Article Data: 45

Chemical Properties

• Melting Point: 145-146°C
• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.189g/cm³
• Refractive Index: 1.544
• BRN: 2651843
• CAS DataBase Reference: 3,4-DIMETHOXYBENZHYDRAZIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-DIMETHOXYBENZHYDRAZIDE(41764-74-3)
• EPA Substance Registry System: 3,4-DIMETHOXYBENZHYDRAZIDE(41764-74-3)

Safety Data

• Hazard Codes: Xi
• Statements: R36/37/38:Irritating to eyes, respiratory system and skin.
• Safety Statements: S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.; S36:Wear suitable prot
• Hazardous Substances Data: 41764-74-3(Hazardous Substances Data)

Usage

General Description

3,4-DIMETHOXYBENZHYDRAZIDE, also known as 3,4-dimethoxybenzohydrazide, is a chemical compound with the molecular formula C9H12N2O3. It is a white to off-white solid that is soluble in organic solvents. 3,4-DIMETHOXYBENZHYDRAZIDE is mainly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It is also utilized in the production of dyes and pigments. The compound is known to have potential as a drug delivery vehicle and has been investigated for its anti-inflammatory and analgesic properties. 3,4-DIMETHOXYBENZHYDRAZIDE should be handled with care and in accordance with all safety guidelines, due to its potential hazards and risks to human health and the environment.

InChI:InChI=1/C9H12N2O3/c1-13-7-4-3-6(9(12)11-10)5-8(7)14-2/h3-5H,10H2,1-2H3,(H,11,12)

Upstream product

• 3535-37-3 3,4-dimethoxybenzoic acid chloride 
• 93-07-2 Veratric acid 
• 120-14-9 3,4-dimethoxy-benzaldehyde 
• 121-34-6 3-methoxy-4-hydroxybenzoic acid 
• 3943-77-9 ethyl veratrate 
• 2150-38-1 methyl 3,4-dimethoxybenzoate 

Downstream Products

• 13321-98-7 N-[5-(3,4-dimethoxy-phenyl)-[1,3,4]oxadiazol-2-yl]-benzenesulfonamide 
• 91759-67-0 C₁₆H₁₇N₃O₃S 
• 331260-82-3 C₁₅H₁₅N₃O₃ 
• 113905-22-9 C₁₄H₁₅N₃O₃ 
• 357206-45-2 C₁₄H₁₄N₂O₃S 
• 113143-36-5 N'-((1H-indol-3-yl)methylene)-3,4-dimethoxybenzohydrazide 
• 884085-46-5 C₁₇H₁₆N₂O₅ 
• 325473-01-6 3,4-dimethoxybenzoic acid (4-diethylamino-2-hydroxybenzylidene)hydrazide 
• 354560-42-2 C₁₇H₁₅F₃N₂O₃ 
• 301326-92-1 C₁₆H₁₅N₃O₅ 
• 357206-37-2 C₁₆H₁₅FN₂O₃ 
• 475428-96-7 C₂₂H₂₀N₂O₄ 
• 394687-28-6 C₁₆H₁₅N₃O₆ 

Relevant articles and documents

Novel arylcarbamate-N-acylhydrazones derivatives as promising BuChE inhibitors: Design, synthesis, molecular modeling and biological evaluation

A novel series of arylcarbamate-N-acylhydrazones derivatives have been designed and synthesized as potential anti-cholinesterase agents. In vitro studies revealed that these compounds demonstrated selective for butyrylcholinesterase (BuChE) with potent inhibitory activity. The compounds 10a-d, 12b and 12d were the most potent BuChE inhibitors with IC50 values of 0.07–2.07 μM, highlighting the compound 10c (IC50 = 0.07 μM) which showed inhibitory activity 50 times greater than the reference drug donepezil (IC50 = 3.54 μM). The activity data indicates that the position of the carbamate group in the aromatic ring has a greater influence on the inhibitory activity of the derivatives. The enzyme kinetics studies indicate that the compound 10c has a non-competitive inhibition against BuChE with Ki value of 0.097 mM. Molecular modeling studies corroborated the in vitro inhibitory mode of interaction and show that compound 10c is stabilized into hBuChE by strong hydrogen bond interaction with Tyr128, π-π stacking interaction with Trp82 and CH?O interactions with His438, Gly121 and Glu197. Based on these data, compound 10c was identified as low-cost promising candidate for a drug prototype for AD treatment.

COMPOUNDS HAVING EXCITED STATE INTRAMOLECULAR PROTON TRANSFER (ESIPT) CHARACTER FOR USE IN TREATING AND/OR PREVENTING SUNBURN AND/OR PREVENTING U.V. DAMAGE

This disclosure relates to use of cashew nut shell liquid (CNSL) phenolics in the manufacture of molecules having ESIPT character, wherein said molecules are UVA and/or UVB absorbers, and further wherein said molecules are formulated as protectants against UVA and/or UVB radiation. The disclosure extends to use of CNSL in the manufacture of compositions including molecules having ESIPT character for treating and/or preventing sunburn and/or preventing U.V. damage.

New imidazo[2,1-: B] thiazole-based aryl hydrazones: Unravelling their synthesis and antiproliferative and apoptosis-inducing potential

Herein, we have designed and synthesized new imidazo[2,1-b]thiazole-based aryl hydrazones (9a-w) and evaluated their anti-proliferative potential against a panel of human cancer cell lines. Among the synthesized compounds, 9i and 9m elicited promising cytotoxicity against the breast cancer cell line MDA-MB-231 with IC50 values of 1.65 and 1.12 μM, respectively. Cell cycle analysis revealed that 9i and 9m significantly arrest MDA-MB-231 cells in the G0/G1 phase. In addition, detailed biological studies such as annexin V-FITC/propidium iodide, DCFH-DA, JC-1 and DAPI staining assays revealed that 9i and 9m triggered apoptosis in MDA-MB-213 cells. Overall, the current work demonstrated the cytotoxicity and apoptosis-inducing potential of 9i and 9m in breast cancer cells and suggested that they could be explored as promising antiproliferative leads in the future. This journal is